ARQT Valuation

Arcutis Biotherapeutics Inc

Add to Watchlist

Advanced Chart

25.310

+0.39(1.565%)1D

ARQT Relative Valuation

ARQT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARQT is overvalued; if below, it's undervalued.

Historical Valuation

Arcutis Biotherapeutics Inc (ARQT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 25.31 is considered Overvalued compared with the five-year average of -13.14. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 7.06 to 11.28 according to relative valuation methord. Compared to the current price of 25.31 USD , Arcutis Biotherapeutics Inc is Overvalued By 124.35%.

Relative Value

Fair Zone

7.06-11.28

Current Price：25.31

124.35%

Overvalued

124.99

Trailing

Forward

31.48

EV/EBITDA

Arcutis Biotherapeutics Inc. (ARQT) has a current EV/EBITDA of 31.48. The 5-year average EV/EBITDA is -13.83. The thresholds are as follows: Strongly Undervalued below -87.13, Undervalued between -87.13 and -50.48, Fairly Valued between 22.82 and -50.48, Overvalued between 22.82 and 59.47, and Strongly Overvalued above 59.47. The current Forward EV/EBITDA of 31.48 falls within the Overvalued range.

31.63

EV/EBIT

Arcutis Biotherapeutics Inc. (ARQT) has a current EV/EBIT of 31.63. The 5-year average EV/EBIT is -16.03. The thresholds are as follows: Strongly Undervalued below -102.94, Undervalued between -102.94 and -59.49, Fairly Valued between 27.43 and -59.49, Overvalued between 27.43 and 70.88, and Strongly Overvalued above 70.88. The current Forward EV/EBIT of 31.63 falls within the Overvalued range.

25.31

Arcutis Biotherapeutics Inc. (ARQT) has a current PS of 25.31. The 5-year average PS is 103.04. The thresholds are as follows: Strongly Undervalued below -253.58, Undervalued between -253.58 and -75.27, Fairly Valued between 281.35 and -75.27, Overvalued between 281.35 and 459.66, and Strongly Overvalued above 459.66. The current Forward PS of 25.31 falls within the Historic Trend Line -Fairly Valued range.

62.25

P/OCF

Arcutis Biotherapeutics Inc. (ARQT) has a current P/OCF of 62.25. The 5-year average P/OCF is -4.19. The thresholds are as follows: Strongly Undervalued below -45.72, Undervalued between -45.72 and -24.95, Fairly Valued between 16.58 and -24.95, Overvalued between 16.58 and 37.34, and Strongly Overvalued above 37.34. The current Forward P/OCF of 62.25 falls within the Strongly Overvalued range.

48.25

P/FCF

Arcutis Biotherapeutics Inc. (ARQT) has a current P/FCF of 48.25. The 5-year average P/FCF is 5.66. The thresholds are as follows: Strongly Undervalued below -64.51, Undervalued between -64.51 and -29.42, Fairly Valued between 40.75 and -29.42, Overvalued between 40.75 and 75.84, and Strongly Overvalued above 75.84. The current Forward P/FCF of 48.25 falls within the Overvalued range.

Arcutis Biotherapeutics Inc (ARQT) has a current Price-to-Book (P/B) ratio of 19.26. Compared to its 3-year average P/B ratio of 7.50 , the current P/B ratio is approximately 156.76% higher. Relative to its 5-year average P/B ratio of 6.06, the current P/B ratio is about 217.58% higher. Arcutis Biotherapeutics Inc (ARQT) has a Forward Free Cash Flow (FCF) yield of approximately -1.07%. Compared to its 3-year average FCF yield of -31.25%, the current FCF yield is approximately -96.57% lower. Relative to its 5-year average FCF yield of -24.47% , the current FCF yield is about -95.62% lower.

19.26

P/B

Median3y

7.50

Median5y

6.06

-1.07

FCF Yield

Median3y

-31.25

Median5y

-24.47

Competitors Valuation Multiple

The average P/S ratio for ARQT's competitors is 19.83, providing a benchmark for relative valuation. Arcutis Biotherapeutics Inc Corp (ARQT) exhibits a P/S ratio of 25.31, which is 27.60% above the industry average. Given its robust revenue growth of 121.69%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARQT.O

Arcutis Biotherapeutics Inc

Ocular Therapeutix Inc

Travere Therapeutics Inc

Agios Pharmaceuticals Inc

43.24

43.69%

2.52B

Performance Decomposition

Market capitalization of ARQT increased by 94.10% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 44.76M to 99.22M.

The secondary factor is the P/E Change, contributed 80.46%to the performance.

Overall, the performance of ARQT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

121.69%

44.76M → 99.22M

Revenue Growth

-108.05%

-92.81 → 7.47

Margin Expansion

80.46%

-40.00 → -72.18

P/E Change

94.10%